Long-term outcomes of patients with Crohn's disease who received infliximab or adalimumab as the first-line biologics

Toshihiro Inokuchi, Sakuma Takahashi, Sakiko Hiraoka, Tatsuya Toyokawa, Shinjiro Takagi, Koji Takemoto, Jiro Miyaike, Tsuyoshi Fujimoto, Reiji Higashi, Yuki Morito, Toru Nawa, Seiyuu Suzuki, Mamoru Nishimura, Masafumi Inoue, Jun Kato, Hiroyuki Okada

Research output: Contribution to journalArticle

Abstract

Background and Aim: Although previous studies compared the efficacy of infliximab (IFX) versus adalimumab (ADA) as the first-line biologics for Crohn's disease (CD), the difference in long-term prognosis based on which biologic was used first has scarcely been reported. In particular, the clinical courses after loss of response (LOR) of the first-line biologics are largely unknown. Methods: A multicenter, retrospective study was performed. Disease courses of biologic-naïve CD patients who were started on IFX or ADA treatment were evaluated, even after LOR of the initial biologics. Results: In total, 263 CD patients were eligible for analysis, 183 were treated with IFX first, and 80 were treated with ADA first. The median observation period was 64.2 months. The cumulative steroid-free remission rates and surgery-free rates did not differ significantly between the patients treated with IFX first and those treated with ADA first (log-rank test P = 0.42 and P = 0.74, respectively). In addition, no significant difference was observed in the rate of occurrence of events associated with ineffectiveness (modification of anti-tumor necrosis factor treatment including intensification, switch, discontinuation, or surgery) between the patient groups (log-rank test P = 0.62). The patients treated with IFX first were likely to discontinue the agent due to adverse events, whereas those treated with ADA first were likely to discontinue due to treatment failure or LOR. Conclusions: No significant difference was observed in the long-term prognosis between biologic-naïve patients with CD who were started treatment with IFX first and ADA first.

Original languageEnglish
JournalJournal of Gastroenterology and Hepatology (Australia)
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Biological Products
Crohn Disease
Treatment Failure
Multicenter Studies
Adalimumab
Infliximab
Therapeutics
Retrospective Studies
Tumor Necrosis Factor-alpha
Steroids
Observation

Keywords

  • adalimumab
  • anti-tumor necrosis factor agent
  • Crohn's disease
  • infliximab

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Long-term outcomes of patients with Crohn's disease who received infliximab or adalimumab as the first-line biologics. / Inokuchi, Toshihiro; Takahashi, Sakuma; Hiraoka, Sakiko; Toyokawa, Tatsuya; Takagi, Shinjiro; Takemoto, Koji; Miyaike, Jiro; Fujimoto, Tsuyoshi; Higashi, Reiji; Morito, Yuki; Nawa, Toru; Suzuki, Seiyuu; Nishimura, Mamoru; Inoue, Masafumi; Kato, Jun; Okada, Hiroyuki.

In: Journal of Gastroenterology and Hepatology (Australia), 01.01.2019.

Research output: Contribution to journalArticle

Inokuchi, T, Takahashi, S, Hiraoka, S, Toyokawa, T, Takagi, S, Takemoto, K, Miyaike, J, Fujimoto, T, Higashi, R, Morito, Y, Nawa, T, Suzuki, S, Nishimura, M, Inoue, M, Kato, J & Okada, H 2019, 'Long-term outcomes of patients with Crohn's disease who received infliximab or adalimumab as the first-line biologics', Journal of Gastroenterology and Hepatology (Australia). https://doi.org/10.1111/jgh.14624
Inokuchi, Toshihiro ; Takahashi, Sakuma ; Hiraoka, Sakiko ; Toyokawa, Tatsuya ; Takagi, Shinjiro ; Takemoto, Koji ; Miyaike, Jiro ; Fujimoto, Tsuyoshi ; Higashi, Reiji ; Morito, Yuki ; Nawa, Toru ; Suzuki, Seiyuu ; Nishimura, Mamoru ; Inoue, Masafumi ; Kato, Jun ; Okada, Hiroyuki. / Long-term outcomes of patients with Crohn's disease who received infliximab or adalimumab as the first-line biologics. In: Journal of Gastroenterology and Hepatology (Australia). 2019.
@article{5c100410d12a4336bfaaeb5922ff9d46,
title = "Long-term outcomes of patients with Crohn's disease who received infliximab or adalimumab as the first-line biologics",
abstract = "Background and Aim: Although previous studies compared the efficacy of infliximab (IFX) versus adalimumab (ADA) as the first-line biologics for Crohn's disease (CD), the difference in long-term prognosis based on which biologic was used first has scarcely been reported. In particular, the clinical courses after loss of response (LOR) of the first-line biologics are largely unknown. Methods: A multicenter, retrospective study was performed. Disease courses of biologic-na{\"i}ve CD patients who were started on IFX or ADA treatment were evaluated, even after LOR of the initial biologics. Results: In total, 263 CD patients were eligible for analysis, 183 were treated with IFX first, and 80 were treated with ADA first. The median observation period was 64.2 months. The cumulative steroid-free remission rates and surgery-free rates did not differ significantly between the patients treated with IFX first and those treated with ADA first (log-rank test P = 0.42 and P = 0.74, respectively). In addition, no significant difference was observed in the rate of occurrence of events associated with ineffectiveness (modification of anti-tumor necrosis factor treatment including intensification, switch, discontinuation, or surgery) between the patient groups (log-rank test P = 0.62). The patients treated with IFX first were likely to discontinue the agent due to adverse events, whereas those treated with ADA first were likely to discontinue due to treatment failure or LOR. Conclusions: No significant difference was observed in the long-term prognosis between biologic-na{\"i}ve patients with CD who were started treatment with IFX first and ADA first.",
keywords = "adalimumab, anti-tumor necrosis factor agent, Crohn's disease, infliximab",
author = "Toshihiro Inokuchi and Sakuma Takahashi and Sakiko Hiraoka and Tatsuya Toyokawa and Shinjiro Takagi and Koji Takemoto and Jiro Miyaike and Tsuyoshi Fujimoto and Reiji Higashi and Yuki Morito and Toru Nawa and Seiyuu Suzuki and Mamoru Nishimura and Masafumi Inoue and Jun Kato and Hiroyuki Okada",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/jgh.14624",
language = "English",
journal = "Journal of Gastroenterology and Hepatology (Australia)",
issn = "0815-9319",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Long-term outcomes of patients with Crohn's disease who received infliximab or adalimumab as the first-line biologics

AU - Inokuchi, Toshihiro

AU - Takahashi, Sakuma

AU - Hiraoka, Sakiko

AU - Toyokawa, Tatsuya

AU - Takagi, Shinjiro

AU - Takemoto, Koji

AU - Miyaike, Jiro

AU - Fujimoto, Tsuyoshi

AU - Higashi, Reiji

AU - Morito, Yuki

AU - Nawa, Toru

AU - Suzuki, Seiyuu

AU - Nishimura, Mamoru

AU - Inoue, Masafumi

AU - Kato, Jun

AU - Okada, Hiroyuki

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background and Aim: Although previous studies compared the efficacy of infliximab (IFX) versus adalimumab (ADA) as the first-line biologics for Crohn's disease (CD), the difference in long-term prognosis based on which biologic was used first has scarcely been reported. In particular, the clinical courses after loss of response (LOR) of the first-line biologics are largely unknown. Methods: A multicenter, retrospective study was performed. Disease courses of biologic-naïve CD patients who were started on IFX or ADA treatment were evaluated, even after LOR of the initial biologics. Results: In total, 263 CD patients were eligible for analysis, 183 were treated with IFX first, and 80 were treated with ADA first. The median observation period was 64.2 months. The cumulative steroid-free remission rates and surgery-free rates did not differ significantly between the patients treated with IFX first and those treated with ADA first (log-rank test P = 0.42 and P = 0.74, respectively). In addition, no significant difference was observed in the rate of occurrence of events associated with ineffectiveness (modification of anti-tumor necrosis factor treatment including intensification, switch, discontinuation, or surgery) between the patient groups (log-rank test P = 0.62). The patients treated with IFX first were likely to discontinue the agent due to adverse events, whereas those treated with ADA first were likely to discontinue due to treatment failure or LOR. Conclusions: No significant difference was observed in the long-term prognosis between biologic-naïve patients with CD who were started treatment with IFX first and ADA first.

AB - Background and Aim: Although previous studies compared the efficacy of infliximab (IFX) versus adalimumab (ADA) as the first-line biologics for Crohn's disease (CD), the difference in long-term prognosis based on which biologic was used first has scarcely been reported. In particular, the clinical courses after loss of response (LOR) of the first-line biologics are largely unknown. Methods: A multicenter, retrospective study was performed. Disease courses of biologic-naïve CD patients who were started on IFX or ADA treatment were evaluated, even after LOR of the initial biologics. Results: In total, 263 CD patients were eligible for analysis, 183 were treated with IFX first, and 80 were treated with ADA first. The median observation period was 64.2 months. The cumulative steroid-free remission rates and surgery-free rates did not differ significantly between the patients treated with IFX first and those treated with ADA first (log-rank test P = 0.42 and P = 0.74, respectively). In addition, no significant difference was observed in the rate of occurrence of events associated with ineffectiveness (modification of anti-tumor necrosis factor treatment including intensification, switch, discontinuation, or surgery) between the patient groups (log-rank test P = 0.62). The patients treated with IFX first were likely to discontinue the agent due to adverse events, whereas those treated with ADA first were likely to discontinue due to treatment failure or LOR. Conclusions: No significant difference was observed in the long-term prognosis between biologic-naïve patients with CD who were started treatment with IFX first and ADA first.

KW - adalimumab

KW - anti-tumor necrosis factor agent

KW - Crohn's disease

KW - infliximab

UR - http://www.scopus.com/inward/record.url?scp=85062363609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062363609&partnerID=8YFLogxK

U2 - 10.1111/jgh.14624

DO - 10.1111/jgh.14624

M3 - Article

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

SN - 0815-9319

ER -